Overview

Parallel Biosystems provides a drug discovery platform that uses immune organoids, artificial intelligence (AI), and robotics to model human diseases and develop immunotherapies. It offers services to pharmaceutical companies, biotech firms, and research institutions, charging service fees, licensing, and milestone payments. The platform works by growing miniaturized human immune organoids in the lab, applying AI to analyze results and guide experiments, and using robotics to automate workflows, enabling faster, cheaper, and more accurate drug discovery than traditional methods. What sets Parallel Biosystems apart is its combination of human-relevant organoid models with AI analytics and automated lab systems, aiming to produce therapies that work across diverse populations. The company’s goal is to accelerate the development of safer and more effective drugs, speeding therapies from research to patients and expanding options for cancer, autoimmune, and age-related diseases.

YC Company

Significant Headcount Growth